Media ReleasesCyclopharm

View All Cyclopharm News

Cyclopharm - Managing Director's Address to Shareholders

Good morning ladies and gentlemen, my name is James McBrayer, the Managing Director of Cyclopharm.

Slide 7 – Financial Highlights

To begin, I would like to provide a review of our financial performance in 2020. During the year, we reported record Group Sales of $14.7 million, up 4.2% from the previous year, and buoyed by $2.2 million of new third-party distribution revenue. This new thirdparty sales growth more than offset the negative revenue impact of COVID-19 across the business. These results places the Company in a strong financial position as we return to more normal trading conditions and growth, post-COVID.

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.